All Posts Tagged With: "BIIB"
(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat
The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of...
(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin
Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation...
(ALNY) Alnylam Pharmaceuticals Reports Smaller Third Quarter Loss Than Expected
Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider...
(PDLI) PDL BioPharma Meets Earnings Forecast – Beats Revenue Forecast
PDL BioPharma Inc. (PDLI) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(MDCO) The Medicines Company Earnings Well Above on Lower Costs
The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus...
(ELN) Elan Quarterly Report Matches Earnings Estimates
Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago...
(BIIB) Biogen Beats Earnings Forecast by a Wide Margin
Biogen Idec Inc. (BIIB) reported third-quarter earnings per share of $1.33, well above the Zacks Consensus Estimate of $1.20 and the year-earlier figure of $1.09. Excluding the impact of stock-based compensation...
(BIIB) Biogen Idec Delivered Earnings Surprises Over the Past Few Quarters
Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09.
Second Quarter Highlights
Biogen...
(BIIB) Biogen Idec and Roche Holdings Amend Deal
Biogen Idec Inc. (BIIB) and Roche Holdings Ltd. (RHHBY) recently announced that they amended their deal related to antibodies targeting...
(SNY) Sanofi-Aventis Presents Encouraging Data on MS Drug
French pharmaceutical company, Sanofi-Aventis (SNY) recently presented encouraging results on its multiple sclerosis (MS) candidate, teriflunomide. Results from a phase III randomized, double-blind, placebo-controlled...
(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform
We are downgrading Cell Therapeutics, Inc. (
7Oct2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral
We recently downgraded Biogen Idec, Inc. (BIIB) to Neutral from our previous Outperform recommendation. Biogen is one of the world’s largest biotechnology companies. Its main areas of focus include neurology,...
(NVS) Novartis AG Earns FDA Approval of Oral Multiple Sclerosis Drug
Novartis AG (NVS) received a huge boost recently with the US Food and Drug Administration (FDA) approving its oral multiple sclerosis (MS) drug, Gilenya. Gilenya...
(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating
We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15.
Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts,...
(BIIB) Biogen Strikes $345 Million Licensing Deal to Develop Treatment For Lou Gehrig’s Disease
Biogen Idec (BIIB) recently entered into an exclusive licensing agreement with Knopp Neurosciences for the development and commercialization of KNS-760704 for the treatment of amyotrophic lateral sclerosis...
(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58.
Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
(CELG) Celgene Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58.
Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
(BIIB) Biogen Idec – Bull of the Day
Biogen Idec (BIIB) reported second-quarter earnings per share of $1.27, well above the year-ago figure of $0.73 and the Zacks Consensus Estimate of $1.08. Revenue increased 11% to $1.2 billion, with Tysabri...
(ALNY) Alnylam Pharmaceuticals’ Second Quarter Loss Down on Lower Costs
Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of...
(MRK) Pharma Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(MDCO) Medicines Company Tops Street Estimates
The Medicines Co. (MDCO) reported a second-quarter profit of 27 cents per share Incorporatedluding the impact of stock-based compensation expense. Second quarter profit was well above the Zacks Consensus...
(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(BIIB) Biogen Idec Second Quarter 2010 Earnings Preview
Biogen Idec Inc. (BIIB) is set to announce its second quarter 2010 results on Tuesday, July 20, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter is $1.08 per share (with...
(BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in Study
Biogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for their phase III study with daclizumab....
(BIIB) Biogen and Roche Announce Cancellation of Candidate Ocrelizumab
Biotech company, Biogen Idec (BIIB) and Swiss pharmaceutical giant Roche (RHHBY) recently announced that they have decided to discontinue...
(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(BMRN) BioMarin Pharma Announces Good News
BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union.
While...